HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Masayasu Matsumoto Selected Research

Atrial Fibrillation

2/2017Relationship Between Infarct Volume and Prothrombin Time-International Normalized Ratio in Ischemic Stroke Patients With Nonvalvular Atrial Fibrillation.
12/2016Predictive factors for bleeding during treatment with rivaroxaban and warfarin in Japanese patients with atrial fibrillation - Subgroup analysis of J-ROCKET AF.
1/2015Early administration of non-vitamin K antagonist oral anticoagulants for acute ischemic stroke patients with atrial fibrillation in comparison with warfarin mostly combined with heparin.
9/2014Can early effective anticoagulation prevent new lesions on magnetic resonance imaging in acute cardioembolic stroke?
5/2014Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial.
5/2014Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF.
2/2014Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial.
1/2014Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age.
11/2013Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF.
1/2013Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Masayasu Matsumoto Research Topics

Disease

57Stroke (Strokes)
01/2023 - 09/2002
37Ischemic Stroke
01/2023 - 09/2005
15Hypertension (High Blood Pressure)
01/2021 - 02/2003
14Atrial Fibrillation
02/2017 - 02/2006
12Ischemia
11/2006 - 01/2002
11Parkinson Disease (Parkinson's Disease)
01/2019 - 06/2002
10Hemorrhage
01/2023 - 02/2006
9Transient Ischemic Attack
05/2019 - 06/2003
8Atherosclerosis
02/2021 - 02/2002
7Infarction (Infarctions)
06/2020 - 04/2004
7Alzheimer Disease (Alzheimer's Disease)
10/2018 - 06/2010
7Carotid Artery Diseases
06/2018 - 06/2002
7Brain Ischemia (Cerebral Ischemia)
07/2017 - 04/2002
7Cerebral Infarction
01/2014 - 06/2002
6Lacunar Stroke
01/2023 - 06/2002
6Myocardial Infarction
10/2021 - 12/2005
6Embolic Stroke
01/2019 - 04/2016
6Neurodegenerative Diseases (Neurodegenerative Disease)
06/2014 - 10/2003
5Inflammation (Inflammations)
05/2018 - 05/2003
5Diabetes Mellitus
04/2018 - 01/2012
5Intracranial Hemorrhages (Intracranial Hemorrhage)
01/2018 - 12/2005
5Embolism (Embolus)
11/2013 - 09/2005
4Hyperlipidemias (Hyperlipidemia)
04/2018 - 07/2012
4Hypoxia (Hypoxemia)
03/2012 - 11/2006
3Pathologic Constriction (Stenosis)
10/2021 - 05/2003
3Dyskinesias (Dyskinesia)
05/2018 - 09/2008
3Neoplasms (Cancer)
03/2018 - 01/2011
3Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
04/2016 - 06/2010
3Dyslipidemias (Dyslipidemia)
01/2016 - 01/2014
3Cognitive Dysfunction
01/2013 - 01/2004
3Atrophy
01/2013 - 06/2003
3Spinocerebellar Ataxias (Spinocerebellar Ataxia)
09/2006 - 02/2004
2Frontotemporal Dementia (Semantic Dementia)
10/2018 - 06/2010
2Myotonic Dystrophy (Dystrophia Myotonica)
10/2018 - 10/2012
2Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome)
10/2018 - 02/2006
2Venous Thrombosis (Deep-Vein Thrombosis)
03/2018 - 09/2016
2Cerebrovascular Disorders (Cerebrovascular Occlusion)
01/2018 - 10/2013
2Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
10/2016 - 04/2004
2Dementia (Dementias)
06/2014 - 01/2004
2Progressive Multifocal Leukoencephalopathy
01/2013 - 01/2012
2Thrombosis (Thrombus)
05/2012 - 09/2005
2Multiple Sclerosis
06/2008 - 08/2003
2Gliosis
02/2006 - 06/2003

Drug/Important Bio-Agent (IBA)

17Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
06/2020 - 12/2005
14Proteins (Proteins, Gene)FDA Link
01/2019 - 01/2002
14Warfarin (Coumadin)FDA LinkGeneric
02/2017 - 09/2005
11Pravastatin (Pravachol)FDA LinkGeneric
06/2020 - 02/2014
9Clopidogrel (Plavix)FDA Link
11/2021 - 01/2008
8RivaroxabanIBA
12/2016 - 01/2012
7Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
11/2021 - 12/2005
7AnticoagulantsIBA
08/2016 - 09/2005
6Cilostazol (Pletal)FDA LinkGeneric
01/2023 - 12/2005
6Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
01/2021 - 09/2005
6C-Reactive ProteinIBA
05/2019 - 03/2004
6UbiquitinIBA
10/2012 - 11/2003
5LDL CholesterolIBA
05/2020 - 04/2016
5alpha-SynucleinIBA
08/2010 - 06/2002
4Prasugrel HydrochlorideFDA Link
02/2021 - 04/2018
4LDL Lipoproteins (beta Lipoproteins)IBA
05/2020 - 01/2017
4Neuroprotective AgentsIBA
01/2019 - 04/2002
4Antihypertensive Agents (Antihypertensives)IBA
01/2017 - 01/2004
4Heparin (Liquaemin)FDA LinkGeneric
09/2016 - 09/2005
4Indicators and Reagents (Reagents)IBA
01/2016 - 02/2003
4Ticlopidine (Ticlid)FDA LinkGeneric
07/2014 - 09/2005
4Apolipoproteins E (ApoE)IBA
07/2006 - 02/2002
4ApolipoproteinsIBA
07/2006 - 02/2002
32'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA
01/2023 - 10/2021
3salicylhydroxamic acid (SHAM)IBA
05/2018 - 03/2002
3fibrin fragment D (D-dimer)IBA
03/2018 - 01/2011
3danaparoid (Orgaran)FDA Link
03/2018 - 01/2011
3LipidsIBA
01/2018 - 06/2014
3tau Proteins (tau Protein)IBA
07/2017 - 02/2006
3Hemoglobins (Hemoglobin)IBA
06/2017 - 07/2012
3Messenger RNA (mRNA)IBA
04/2016 - 01/2002
3Biomarkers (Surrogate Marker)IBA
01/2016 - 07/2009
3Tissue Plasminogen Activator (Alteplase)FDA Link
12/2015 - 01/2014
3Vitamin KFDA Link
01/2015 - 04/2012
3AntibodiesIBA
06/2013 - 12/2006
3Glutamic Acid (Glutamate)FDA Link
05/2003 - 04/2002
2EnzymesIBA
12/2018 - 10/2003
2cilnidipineIBA
06/2018 - 01/2017
2AntigensIBA
01/2017 - 08/2003
2Therapeutic UsesIBA
01/2017 - 11/2011
2CholesterolIBA
02/2014 - 07/2007
2Angiotensin Receptor AntagonistsIBA
12/2013 - 11/2011
2Mefloquine (Lariam)FDA LinkGeneric
01/2013 - 01/2012
2Oxygen (Dioxygen)IBA
05/2012 - 09/2002
2Factor Xa InhibitorsIBA
04/2012 - 01/2012
2Small Interfering RNA (siRNA)IBA
03/2012 - 11/2006
2Angiotensin IIIBA
11/2011 - 04/2011
2Levodopa (L Dopa)FDA LinkGeneric
09/2011 - 09/2008
2Mixed Function Oxygenases (Monooxygenases)IBA
03/2008 - 02/2007
2Proteasome Endopeptidase Complex (Proteasome)IBA
07/2007 - 11/2003
2Bromodeoxyuridine (BrdU)IBA
11/2006 - 03/2002
2Cyclooxygenase 2 (Cyclooxygenase-2)IBA
01/2004 - 05/2003
2Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
11/2003 - 02/2002
2AntioxidantsIBA
11/2002 - 04/2002

Therapy/Procedure

27Therapeutics
01/2023 - 09/2005
8Secondary Prevention
01/2023 - 12/2005
2Aftercare (After-Treatment)
10/2016 - 01/2013